Clinical trial · Interventional
Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris
Analysis of Gut Microbiota, Psoriasis Area and Severity Index, Interleukin-17, Tumor Necrosis Factor -α, Interleukin-10, and Foxp3 in Psoriasis Vulgaris After Supplementation With Lactobacillus Plantarum IS-10506
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection, obesity, smoking, and drugs. The provision of probiotic Lactobacillus plantarum IS-10506, an Indonesian original probiotic strain, is expected to be an effective, safe, and affordable alternative for psoriasis treatment for psoriasis patients in Indonesia. This study aimed to evaluate changes in gut microbiota profile, cytokines IL-17, TNF-a, IL-10, Foxp3, and disease severity of psoriasis vulgaris patients after supplementation with Lactobacillus plantarum IS-10506. The results of this study are expected to be the basis for the use of Lactobacillus plantarum IS-10506 in the therapy of psoriasis vulgaris which is included in the Clinical Practice Guide in Indonesia, which will ultimately help improve the quality of life of psoriasis patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Psoriasis Vulgaris | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lactobacillus Plantarum IS-10506 | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Treatment Group
- description
- In the treatment group, intervention was given in the form of standard therapy and probiotic Lactobacillus plantarum IS 10605 in the amount of 2x1010 CFU for 12 weeks.
- interventionNames
- Drug: Lactobacillus Plantarum IS-10506
- type
- PLACEBO_COMPARATOR
- label
- Placebo Group
- description
- In the placebo group, intervention was given in the form of standard therapy and placebo 2x1 sachets for 12 weeks.
- interventionNames
- Other: Placebo
- type
- NO_INTERVENTION
- label
- Healty Control Group
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: Patient Group Inclusion Criteria: 1. Psoriasis vulgaris patients with or without treatment 2. Mild to moderate degree 3. Age 18-70 years old 4. Willing to give informed consent Healthy Control Group Inclusion Criteria: 1. Undiagnosed as Psoriasis 2. Body mass index (BMI) is matched with the patient group 3. Age 18-70 years old 4. Willing to give Informed Consent Exclusion Criteria: Patient Group Exclusion Criteria: 1. Patients on systemic treatment with corticosteroids, methotrexate, cyclosporine, or biologic agents within 3 months prior to sampling 2. Take oral antibiotics, laxatives, and proton pump inhibitors (PPI) within 14 days before stool sampling 3. Suffering from severe systemic disease, diarrhea 4. Pustular psoriasis patients 5. Take probiotics within 30 days before stool sampling Healthy Control Group Exclusion Criteria: 1. Patients on systemic treatment with corticosteroids, methotrexate, cyclosporine, or biologic agents within 3 months before stool sampling 2. Take oral antibiotics, laxatives, and proton pump inhibitors (PPI) within 14 days before stool sampling 3. Suffering from severe systemic disease, diarrhea
References
Publications (0)
Data not yet available